Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

6 results
12:05 PM, Oct 06, 2017  |  BC Week In Review | Company News  |  Other News

Camino receives $10.8M grant to treat addiction

submit an IND to the FDA in 2020 for Camino's lead compound SBP-0069330 , a metabotropic glutamate receptor subtype 2 ( mGluR2 ; GRM2
12:00 AM, Mar 23, 2015  |  BC Week In Review | Company News  |  Deals

Eli Lilly and Co, Denovo Biopharma deal

of patient outcome. Lilly has the option to reacquire the oral prodrug of LY404039, a metabotropic glutamate receptor subtype 2
3 ( mGluR2 /3) agonist, upon the successful validation of one or more biomarkers. Denovo said …
12:00 AM, Jun 03, 2013  |  BC Week In Review | Company News  |  Other News

Addex neurology news

2004, Addex and J&J partnered to discover, develop and commercialize positive allosteric modulators (PAM) of metabotropic glutamate receptor subtype 2
mGluR2 ) to treat anxiety, schizophrenia and other undisclosed indications. Addex said it will only …
top-line results from developing of ADX71149 . J&J and Addex jointly developed the PAM of mGluR2
12:00 AM, Apr 16, 2012  |  BC Week In Review | Company News  |  Other News

Addex Therapeutics neurology news

of metabotropic glutamate receptor subtype 5 (mGluR5), and ADX71149 is a positive allosteric modulator of mGluR2
12:00 AM, Jul 11, 2011  |  BC Week In Review | Company News  |  Other News

Addex neurology news

testing to Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 , a positive allosteric modulator of mGluR2
12:00 AM, May 17, 2010  |  BC Week In Review | Company News  |  Deals

Addex, J&J deal

front and €4.2 million ($5.4 million) in R&D funding. The positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2
mGluR2 ) is in Phase I testing to treat central nervous system (CNS) disorders, including …